Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | FPR1 | P21462 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31217392 | 1.00 | ADRA1A (0.45) | ADRA1APDE10AMAP3K12ADORA2AADORA1 | |
| SCHEMBL18145687 | 1.00 | ADRA1A (0.45) | ADRA1APDE10AMAP3K12ADORA2AADORA1 | |
| SCHEMBL31217226 | 0.85 | MKNK1 (0.43) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL31217260 | 0.85 | MKNK1 (0.43) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL31217410 | 0.83 | PIK3CD (0.34) | ADRA1A | |
| SCHEMBL31217345 | 0.82 | MTOR (0.35) | MAP3K12 | |
| SCHEMBL18450679 | 0.82 | MTOR (0.35) | MAP3K12 | |
| SCHEMBL31217353 | 0.81 | MKNK1 (0.40) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL15879358 | 0.79 | MAP3K12 (0.37) | PDE10AMAP3K12 | |
| SCHEMBL14701431 | 0.79 | MAP3K12 (0.37) | PDE10AMAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273238-B2 | Indazolones as modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180215764-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-08-02 | — | — | US | disclosed |
| US-9879016-B2 | Indazolones as modulators of TNF signaling | ABBVIE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160304526-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215764-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, TNFRSF9, TNFRSF1A | ADRA1A 440/4885PDE10A 1366/4885MAP3K12 60/4885 |
| US-20160304526-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, TNFRSF9, TNFRSF1A | ADRA1A 440/4885PDE10A 1366/4885MAP3K12 60/4885 |
| US-10273238-B2 | Indazolones as modulators of TNF signaling | TNF, TNFRSF9, TNFRSF1A | ADRA1A 440/4885PDE10A 1366/4885MAP3K12 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.